BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25061297)

  • 1. MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer.
    Passadouro M; Pedroso de Lima MC; Faneca H
    Int J Nanomedicine; 2014; 9():3203-17. PubMed ID: 25061297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.
    Kadera BE; Li L; Toste PA; Wu N; Adams C; Dawson DW; Donahue TR
    PLoS One; 2013; 8(8):e71978. PubMed ID: 23991015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 coupled with HOTAIR to silence MicroRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma.
    Li CH; Xiao Z; Tong JH; To KF; Fang X; Cheng AS; Chen Y
    Int J Cancer; 2017 Jan; 140(1):120-129. PubMed ID: 27594424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma.
    Costa PM; Cardoso AL; Nóbrega C; Pereira de Almeida LF; Bruce JN; Canoll P; Pedroso de Lima MC
    Hum Mol Genet; 2013 Mar; 22(5):904-18. PubMed ID: 23201752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.
    Li CH; To KF; Tong JH; Xiao Z; Xia T; Lai PB; Chow SC; Zhu YX; Chan SL; Marquez VE; Chen Y
    Gastroenterology; 2013 May; 144(5):1086-1097.e9. PubMed ID: 23395645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Anti-miRNAs Oligonucleotides with Low Amounts of Chemotherapeutic Agents for Pancreatic Cancer Therapy.
    Passadouro M; Faneca H
    Methods Mol Biol; 2018; 1699():135-154. PubMed ID: 29086375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manganese superoxide dismutase expression is negatively associated with microRNA-301a in human pancreatic ductal adenocarcinoma.
    Pandit H; Zhang W; Li Y; Agle S; Li X; Li SP; Cui G; Li Y; Martin RC
    Cancer Gene Ther; 2015 Oct; 22(10):481-6. PubMed ID: 26384137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells.
    Dong Q; Li C; Che X; Qu J; Fan Y; Li X; Li Y; Wang Q; Liu Y; Yang X; Qu X
    Oncotarget; 2016 Dec; 7(50):82338-82353. PubMed ID: 27494897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y; Suzuki M; Katsushima K; Shinjo K; Iijima K; Murofushi Y; Naiki-Ito A; Hayashi K; Qiu C; Takahashi A; Tanaka Y; Kawaguchi T; Sugawara M; Kataoka T; Naito M; Miyata K; Kataoka K; Noda T; Gao W; Kataoka H; Takahashi S; Kimura K; Kondo Y
    Cancer Res; 2021 Apr; 81(7):1654-1666. PubMed ID: 33648930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting miR-21 for the therapy of pancreatic cancer.
    Sicard F; Gayral M; Lulka H; Buscail L; Cordelier P
    Mol Ther; 2013 May; 21(5):986-94. PubMed ID: 23481326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1.
    Zhou L; Zhang WG; Wang DS; Tao KS; Song WJ; Dou KF
    Oncol Rep; 2014 Oct; 32(4):1734-40. PubMed ID: 25109303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation, apoptosis, and invasion by sponging miR-625 and miR-892b.
    Hao L; Rong W; Bai L; Cui H; Zhang S; Li Y; Chen D; Meng X
    J Cell Biochem; 2019 Mar; 120(3):3780-3789. PubMed ID: 30382592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma.
    Ben Q; Sun Y; Liu J; Wang W; Zou D; Yuan Y
    Pancreatology; 2020 Jun; 20(4):698-708. PubMed ID: 32354626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA TP73-AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA -200a sponging.
    Miao H; Lu J; Guo Y; Qiu H; Zhang Y; Yao X; Li X; Lu Y
    J Cell Mol Med; 2021 Apr; 25(7):3654-3664. PubMed ID: 33683827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions.
    Ouyang H; Gore J; Deitz S; Korc M
    Oncogene; 2014 Sep; 33(38):4664-74. PubMed ID: 24096486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.
    Gibori H; Eliyahu S; Krivitsky A; Ben-Shushan D; Epshtein Y; Tiram G; Blau R; Ofek P; Lee JS; Ruppin E; Landsman L; Barshack I; Golan T; Merquiol E; Blum G; Satchi-Fainaro R
    Nat Commun; 2018 Jan; 9(1):16. PubMed ID: 29295989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.